Trial Profile
IQUO-Ledger- Prospective non-interventional study for the characterisation of routine practice of Cabazitaxel and other therapyoptions for treatment of patients with metastasizing castration resistent prostate cancer (mCRPC) in established doctors' practice with emphasis on oncological urology - HOPE (NIS Jevtana)
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Antineoplastics; Granulocyte colony-stimulating factors
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms HOPE
- 28 Sep 2012 New trial record